2018 中国糖尿病更具影响力十大研究公布!:CDS2019

2019-11-23 小M MedSci原创

“中国糖尿病十大研究”由中华医学会糖尿病学分会设立、中华糖尿病杂志承办。今年是第四次评选。组委会通过PubMed 共检索出5010 篇由中国学者发表在全球知名期刊的与糖尿病密切相关的文章,经过独立专家评审小组历时2 个月的严格评选,筛选出30 项科学性、创新性俱佳的研究,再经过网络票选,最后经中华医学会糖尿病学分会常委会认真讨论和评议,最终选出10 项2018 年度最具影响力的研究。其颁奖仪式在1

“中国糖尿病十大研究”由中华医学会糖尿病学分会设立、中华糖尿病杂志承办。今年是第四次评选。组委会通过PubMed 共检索出5010 篇由中国学者发表在全球知名期刊的与糖尿病密切相关的文章,经过独立专家评审小组历时2 个月的严格评选,筛选出30 项科学性、创新性俱佳的研究,再经过网络票选,最后经中华医学会糖尿病学分会常委会认真讨论和评议,最终选出10 项2018 年度最具影响力的研究。其颁奖仪式在11月23日的CDS2019大会闭幕式期间举行。

2018 年度中国糖尿病最具影响力十大研究名单公布如下:


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1947125, encodeId=e247194e1255b, content=<a href='/topic/show?id=2ac250319fe' target=_blank style='color:#2F92EE;'>#影响力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50319, encryptionId=2ac250319fe, topicName=影响力)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/L2dMhrxjvSWuPWKZZP1I83Rw21EWia7LVTYJibLQkb4oTibrYLwhnAXntTBWR3FruIzKfNMiaBwhYV0AKNmiaNxfialg/132, createdBy=6ea92500119, createdName=ms9608593228839890, createdTime=Sat Feb 15 03:18:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375813, encodeId=d3513e5813e7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a5226174, createdName=1478e879m90暂无昵称, createdTime=Mon Nov 25 10:43:19 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377638, encodeId=300513e7638fd, content=<a href='/topic/show?id=5dfe4420fc' target=_blank style='color:#2F92EE;'>#CDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4420, encryptionId=5dfe4420fc, topicName=CDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Mon Nov 25 04:18:00 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375759, encodeId=a40b3e5759b3, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sun Nov 24 08:51:32 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042835, encodeId=d11c10428351f, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Nov 23 16:18:00 CST 2019, time=2019-11-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1947125, encodeId=e247194e1255b, content=<a href='/topic/show?id=2ac250319fe' target=_blank style='color:#2F92EE;'>#影响力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50319, encryptionId=2ac250319fe, topicName=影响力)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/L2dMhrxjvSWuPWKZZP1I83Rw21EWia7LVTYJibLQkb4oTibrYLwhnAXntTBWR3FruIzKfNMiaBwhYV0AKNmiaNxfialg/132, createdBy=6ea92500119, createdName=ms9608593228839890, createdTime=Sat Feb 15 03:18:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375813, encodeId=d3513e5813e7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a5226174, createdName=1478e879m90暂无昵称, createdTime=Mon Nov 25 10:43:19 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377638, encodeId=300513e7638fd, content=<a href='/topic/show?id=5dfe4420fc' target=_blank style='color:#2F92EE;'>#CDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4420, encryptionId=5dfe4420fc, topicName=CDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Mon Nov 25 04:18:00 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375759, encodeId=a40b3e5759b3, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sun Nov 24 08:51:32 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042835, encodeId=d11c10428351f, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Nov 23 16:18:00 CST 2019, time=2019-11-23, status=1, ipAttribution=)]
    2019-11-25 1478e879m90暂无昵称

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1947125, encodeId=e247194e1255b, content=<a href='/topic/show?id=2ac250319fe' target=_blank style='color:#2F92EE;'>#影响力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50319, encryptionId=2ac250319fe, topicName=影响力)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/L2dMhrxjvSWuPWKZZP1I83Rw21EWia7LVTYJibLQkb4oTibrYLwhnAXntTBWR3FruIzKfNMiaBwhYV0AKNmiaNxfialg/132, createdBy=6ea92500119, createdName=ms9608593228839890, createdTime=Sat Feb 15 03:18:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375813, encodeId=d3513e5813e7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a5226174, createdName=1478e879m90暂无昵称, createdTime=Mon Nov 25 10:43:19 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377638, encodeId=300513e7638fd, content=<a href='/topic/show?id=5dfe4420fc' target=_blank style='color:#2F92EE;'>#CDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4420, encryptionId=5dfe4420fc, topicName=CDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Mon Nov 25 04:18:00 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375759, encodeId=a40b3e5759b3, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sun Nov 24 08:51:32 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042835, encodeId=d11c10428351f, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Nov 23 16:18:00 CST 2019, time=2019-11-23, status=1, ipAttribution=)]
    2019-11-25 yangpeizhi
  4. [GetPortalCommentsPageByObjectIdResponse(id=1947125, encodeId=e247194e1255b, content=<a href='/topic/show?id=2ac250319fe' target=_blank style='color:#2F92EE;'>#影响力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50319, encryptionId=2ac250319fe, topicName=影响力)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/L2dMhrxjvSWuPWKZZP1I83Rw21EWia7LVTYJibLQkb4oTibrYLwhnAXntTBWR3FruIzKfNMiaBwhYV0AKNmiaNxfialg/132, createdBy=6ea92500119, createdName=ms9608593228839890, createdTime=Sat Feb 15 03:18:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375813, encodeId=d3513e5813e7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a5226174, createdName=1478e879m90暂无昵称, createdTime=Mon Nov 25 10:43:19 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377638, encodeId=300513e7638fd, content=<a href='/topic/show?id=5dfe4420fc' target=_blank style='color:#2F92EE;'>#CDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4420, encryptionId=5dfe4420fc, topicName=CDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Mon Nov 25 04:18:00 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375759, encodeId=a40b3e5759b3, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sun Nov 24 08:51:32 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042835, encodeId=d11c10428351f, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Nov 23 16:18:00 CST 2019, time=2019-11-23, status=1, ipAttribution=)]
    2019-11-24 1ddf0692m34(暂无匿称)

    学习了谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1947125, encodeId=e247194e1255b, content=<a href='/topic/show?id=2ac250319fe' target=_blank style='color:#2F92EE;'>#影响力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50319, encryptionId=2ac250319fe, topicName=影响力)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/L2dMhrxjvSWuPWKZZP1I83Rw21EWia7LVTYJibLQkb4oTibrYLwhnAXntTBWR3FruIzKfNMiaBwhYV0AKNmiaNxfialg/132, createdBy=6ea92500119, createdName=ms9608593228839890, createdTime=Sat Feb 15 03:18:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375813, encodeId=d3513e5813e7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a5226174, createdName=1478e879m90暂无昵称, createdTime=Mon Nov 25 10:43:19 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377638, encodeId=300513e7638fd, content=<a href='/topic/show?id=5dfe4420fc' target=_blank style='color:#2F92EE;'>#CDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4420, encryptionId=5dfe4420fc, topicName=CDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Mon Nov 25 04:18:00 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375759, encodeId=a40b3e5759b3, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sun Nov 24 08:51:32 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042835, encodeId=d11c10428351f, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Nov 23 16:18:00 CST 2019, time=2019-11-23, status=1, ipAttribution=)]
    2019-11-23 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

郭晓蕙教授:基层糖尿病教育与管理:CDS2019

11月20日,中华医学会糖尿病学分会第二十三次全国学术会议(CDS 2019)在厦门国际会展中心盛大召开。北京大学第一医院的郭晓蕙教授对糖尿病患者的教育和管理方面有着深入了解和丰富的经验,在本次年会的基层糖尿病防治专场中,郭教授针对基层糖尿病患者教育与综合管理进行了专题报告,小编在此整理与大家分享。近些年来我国糖尿病患病人数不断增长,如何科学管理患者,延缓疾病的进展是大家共同关注的话题,其中对糖尿

奏响糖尿病防治行动“三部曲”:聚焦前沿、创新管理、注重预防——中华医学会糖尿病学分会第二十三次全国学术会议在厦门隆重开幕!

11月20日—23日,由中华医学会、中华医学会糖尿病学分会主办,厦门市医学会承办的中华医学会糖尿病学分会第二十三次全国学术会议(CDS 2019)在厦门国际会展中心盛大召开!本届年会恰逢新中国成立70周年,健康中国行动(2019-2030年)全面实施之际,CDS 2019以“聚焦前沿、创新管理、注重预防”为主题,奏响健康中国新时代糖尿病防治行动的最强音。同时,CDS经历20多年不断成长、成熟、

聚焦前沿,全体大会精彩纷呈:CDS2019

今日上午,中华医学会糖尿病学分会第二十三次全国学术会议(CDS2019)在美丽的 “海上花园”鹭岛厦门隆重开幕。本次年会围绕 “聚焦前沿、创新管理、注重预防”的主题,将对糖尿病领域数十个专题开展广泛而深入的交流。在全体大会中,中外专家就糖尿病领域热点话题进行了分享与讨论。

如何吃得像个皇帝一样?!:CDS2019

中华医学会糖尿病学分会第二十三次全国学术会议今天在厦门盛大开幕了。本次会议是2019 年国内外糖尿病学术领域的收官之作,是融合国内最高水平学术研究最新进展的学术盛宴。会议将以“聚焦前沿、创新管理、注重预防”为主题,学术内容精彩纷呈,一起来看看小编为您精选的大会第一天内容吧! 在“点亮餐后血糖”的会议主场,中山大学孙逸仙纪念医院李焱教授为大家带来一场生动的“How to Eat Like a Kin

郭立新教授:运动是良医——糖尿病患者很大获益的运动方式:CDS2019

令记者印象最为深刻的是,郭立新教授用轻松、幽默的方式,向与会者生动讲解了糖尿病患者最大获益的运动方式,现撷取精要,与您分享。

SGLT2抑制剂临床应用专家指导建议解读:CDS2019

新型降糖药物如SGLT2抑制剂、DPP-4抑制剂、GLP1-RA陆续在国内上市,部分药品进入国家医保目录及国家基药目录,临床应用日趋广泛。广大一线基层医生缺乏对新型糖药物的药物特性、指南地位、临床获益、特殊人群应用及可能副作用的深入理解,严重制约药物合理应用。新型降糖药物的大型临床循证证据不断揭晓,相关基础研究不断深入,真实世界研究数据相继报道,如问综合且合理解读相关指南文献,服务临床实践,日